Compare
Jasper Therapeutics, Inc. vs CEL SCI Corp vs Champions Oncology, Inc. vs Cognition Therapeutics Inc
| Latest fiscal year | Jasper Therapeutics, Inc. JSPR | CEL SCI Corp CVM | Champions Oncology, Inc. CSBR | Cognition Therapeutics Inc CGTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2026-04-30 | 2025-12-31 |
| Revenue | n/a | n/a | $59.42M | n/a |
| Revenue growth (YoY) | n/a | n/a | +4.4% | n/a |
| Gross margin | n/a | n/a | 48.0% (computed) | n/a |
| Operating margin | n/a | n/a | -1.9% | n/a |
| Net margin | n/a | n/a | -2.0% | n/a |
| Net income | -$75.80M | -$25.41M | -$1.18M | -$23.49M |
| EPS (Diluted) | -$3.95 | -$6.27 | -$0.08 | -$0.32 |
| Operating cash flow | -$77.16M | -$17.12M | -$4.47M | -$24.59M |
| Free cash flow | n/a | -$17.16M | -$5.04M | n/a |
| Cash & equivalents | $28.69M | n/a | n/a | $36.81M |
| Total assets | $35.78M | $28.16M | $26.99M | $48.39M |
| Total liabilities | $31.63M | $12.20M | $22.92M | $14.12M |
| Shareholders' equity | $4.15M | $15.96M | $3.94M | $34.27M |
| Return on year-end equity | n/m | -159.2% | -29.8% | -68.5% |
| Shares outstanding | 28.00M | 8.02M | 13.89M | 88.90M |
Revenue, most recent five fiscal years
| Fiscal year | Jasper Therapeutics, Inc. | CEL SCI Corp | Champions Oncology, Inc. | Cognition Therapeutics Inc |
|---|---|---|---|---|
| Latest | n/a | $264.0K Ended 2014-09-30 | $59.42M Ended 2026-04-30 | n/a |
| 1 year earlier | n/a | $159.6K Ended 2013-09-30 | $56.94M Ended 2025-04-30 | n/a |
| 2 years earlier | n/a | $254.6K Ended 2012-09-30 | $50.16M Ended 2024-04-30 | n/a |
| 3 years earlier | n/a | $956.2K Ended 2011-09-30 | $53.87M Ended 2023-04-30 | n/a |
| 4 years earlier | n/a | n/a | $49.11M Ended 2022-04-30 | n/a |